文献速递类风湿关节炎

早期类风湿关节炎患者三种生物制剂与传统治疗相比24周缓解率的性别差异(NORD-STAR):一项随机对照试验的事后分析

Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial.
PubMed 文献 · Lancet Rheumatol · 2022-08-23

NORD-STAR试验事后分析纳入812例早期类风湿关节炎患者,比较四种治疗24周临床疾病活动指数(CDAI)缓解率的性别差异。观察到的24周CDAI缓解率在男性中数值上高于女性,所有治疗组均如此。校正分析中仅托珠单抗组男性与女性差异显著(交互作用P=0.015),男性托珠单抗组较男性传统治疗组缓解概率高0.12(95%CI 0.00至0.23),女性托珠单抗组较女性传统治疗组低0.05(95%CI -0.13至0.02)。

要点

  • 24周CDAI缓解率男性数值上高于女性:传统治疗55%对50%,培塞利珠单抗57%对52%,阿巴西普65%对51%,托珠单抗61%对40%。
  • 校正分析仅托珠单抗组性别交互作用显著(P=0.015),男性托珠单抗组较男性传统治疗组缓解概率高0.12(95%CI 0.00至0.23)。
  • 女性托珠单抗组较女性传统治疗组缓解概率低0.05(95%CI -0.13至0.02),未达统计学显著。

核心结论

  • 24周时四种治疗组男性缓解率均数值上高于女性,提示这一性别差异可能与治疗无关。
  • 托珠单抗(IL-6抑制剂)组男女差异显著大于传统治疗组,提示可能存在IL-6阻断特异的额外性别效应。

研究设计与样本

  • NORD-STAR为多中心、研究者发起、评估者盲法、4期随机对照试验,在丹麦、芬兰、冰岛、挪威、瑞典和荷兰进行。
  • 新诊断、未使用过改善病情抗风湿药、年龄18岁及以上、症状持续时间小于24个月的早期类风湿关节炎患者按1:1:1:1随机分配至传统治疗、培塞利珠单抗、阿巴西普或托珠单抗。
  • 2012年12月14日至2018年12月11日共纳入812例患者:传统治疗217例、培塞利珠单抗203例、阿巴西普204例、托珠单抗188例;女性561例(69%),男性251例(31%)。
  • 本事后分析采用逻辑广义估计方程(GEE),模型含治疗、时间、性别及相关交互项,以传统治疗为参照,报告校正平均边际缓解率差异(风险差)及95%CI。

主要发现

  • 24周观察到的CDAI缓解率男性数值上高于女性:传统治疗55%对50%,培塞利珠单抗57%对52%,阿巴西普65%对51%,托珠单抗61%对40%。
  • 校正分析中仅托珠单抗组男女差异显著(交互作用P=0.015)。
  • 男性托珠单抗组较男性传统治疗组平均随时间CDAI缓解概率高0.12(95%CI 0.00至0.23)。
  • 女性托珠单抗组较女性传统治疗组缓解概率低0.05(95%CI -0.13至0.02)。

关键数值与推荐

  • CDAI缓解定义为CDAI评分≤2.8。
  • 共纳入812例患者,女性561例(69%),男性251例(31%)。
  • 托珠单抗组性别交互作用P=0.015。
  • 男性托珠单抗组较男性传统治疗组风险差0.12(95%CI 0.00至0.23)。
  • 女性托珠单抗组较女性传统治疗组风险差-0.05(95%CI -0.13至0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis is a chronic inflammatory disease with a well-recognised female preponderance. In this post-hoc analysis of the NORD-STAR trial, we aimed to examine sex differences in remission rates with three different biological treatments combined with methotrexate versus active conventional treatment over 24 weeks, in patients with early rheumatoid arthritis. METHODS: NORD-STAR was a multicentre, investigator-initiated, assessor-blinded, phase 4, randomised, controlled trial of early rheumatoid arthritis, done in Denmark, Finland, Iceland, Norway, Sweden, and the Netherlands. Newly diagnosed patients, naive to disease-modifying antirheumatic drugs, aged 18 years or older with early rheumatoid arthritis and with a symptom duration less than 24 months were randomly assigned (1:1:1:1) to receive active conventional treatment, certolizumab-pegol, abatacept, or tocilizumab. Sex was reported in case report forms by study physicians or by study nurses. Data on gender were not collected. Remission outcomes were analysed with logistic generalised estimating equations (GEE), using a logit link and exchangeable correlation matrix. The model included treatment, time, sex, and the relevant interactions. For this post-hoc analysis, the co-primary outcomes were differences in Clinical Disease Activity Index (CDAI) remission (CDAI score ≤2·8) between sexes over time and at week 24, assessed with interaction terms (men vs women within each treatment comparison) and using active conventional treatment as the reference. We present adjusted average marginal differences in remission rates (risk differences) with 95% CIs. FINDINGS: Between Dec 14, 2012, and Dec 11, 2018, 812 patients were enrolled and randomly assigned; 217 received active conventional treatment, 203 received certolizumab-pegol, 204 received abatacept, and 188 received tocilizumab. All 812 patients were included in this analysis; 561 (69%) were women and 251 (31%) were men. Observed CDAI remission rates at 24 weeks were numerically higher among men than among women despite comparable disease activity at baseline (55% vs 50% with active conventional treatment, 57% vs 52% with certolizumab-pegol, 65% vs 51% with abatacept, and 61% vs 40% with tocilizumab). In the adjusted analysis, with active conventional treatment as the reference, the only significant difference between men and women was in the tocilizumab group (pinteraction=0·015); men in the tocilizumab group had a higher probability of CDAI remission, on average over time, than did men in the active conventional treatment group (0·12; 95% CI 0·00 to 0·23), whereas women in the tocilizumab group had a lower probability of remission than did women in the active conventional treatment group (-0·05, 95% CI -0·13 to 0·02). INTERPRETATION: Numerically higher remission rates were observed in men than in women in all four treatment groups at week 24, suggesting that this generalised sex difference is not related to the treatment. The difference between men and women was significantly greater with tocilizumab, an interleukin (IL)-6 inhibitor, than with active conventional treatment, suggesting a possible additional sex-based effect specific for IL-6 blockade. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lend K, van Vollenhoven RF, Lampa J, et al. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial. Lancet Rheumatol. 2022. PMID: 38265967. doi:10.1016/S2665-9913(22)00186-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。